Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$91.84 USD

91.84
220,091

+0.05 (0.05%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $91.86 +0.02 (0.02%) 5:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (151 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Amedisys (AMED) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amedisys (AMED) Q3 Earnings and Revenues Lag Estimates

Amedisys (AMED) delivered earnings and revenue surprises of -9.26% and 0.99%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Acquires Majority Stake in Shield Healthcare

Henry Schein (HSIC) completes the majority investment in Shield Healthcare, Inc.

Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?

Here is how Amedisys (AMED) and Cybin Inc. (CYBN) have performed compared to their sector so far this year.

Philips (PHG) Aids Clinicians With New Monitoring Solution

Philips (PHG) launches Visual Patient Avatar to help anesthesiologists with situational awareness in operating rooms, boosting their clinical confidence.

Are Medical Stocks Lagging Clover Health Investments (CLOV) This Year?

Here is how Clover Health Investments, Corp. (CLOV) and Amedisys (AMED) have performed compared to their sector so far this year.

Encompass Health (EHC) Up 2.9% Since Last Earnings Report: Can It Continue?

Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Dip

Strength in Hugh Acuity Care segment and Hospice division drive Amedisys (AMED) Q2 performance.

Company News for Jul 27, 2023

Companies in The News Are: AMED,SNAP,UNP,WFC

Amedisys (AMED) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Amedisys (AMED) Tops Q2 Earnings Estimates

Amedisys (AMED) delivered earnings and revenue surprises of 28.04% and 2.47%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Addus HomeCare (ADUS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Addus HomeCare (ADUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Amedisys (AMED) Q2 Earnings Expected to Decline

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amedisys (AMED) to Advance Value-Based Care With Optum Merger

Amedisys' (AMED) combination with Optum brings together two organizations committed to offering patients and their families compassionate, value-based comprehensive care.

UnitedHealth Group (UNH) Expands Home Healthcare Business

UnitedHealth Group (UNH) boosts home healthcare presence with the acquisition of Amedisys for $3.3 billion

Are Options Traders Betting on a Big Move in Amedisys (AMED) Stock?

Investors need to pay close attention to Amedisys (AMED) stock based on the movements in the options market lately.

Debanjana Dey headshot

4 Stocks to Hold in a Challenging Outpatient Home Health Industry

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE, AMED and ADUS are well poised to gain.

UnitedHealth (UNH) Intends to Buy Amedisys to Boost Home-Health

UnitedHealth (UNH) offers to combine its Optum business with Amedisys to expand its reach in the healthcare-at-home market.

Strength Seen in Amedisys (AMED): Can Its 15.4% Jump Turn into More Strength?

Amedisys (AMED) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Amedisys (AMED) Q1 Earnings Beat Estimates, Margins Dip

Amedisys (AMED) sees a year-over-year decline in the Hospice segment's revenues.

Amedisys (AMED) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Amedisys (AMED) Q1 Earnings Top Estimates

Amedisys (AMED) delivered earnings and revenue surprises of 16.28% and 0.58%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Amedisys (AMED) New Buyouts Aid Growth, CMS Ruling Unfavorable

For Amedisys (AMED), dealing with the continuous shortage of clinical labo, in nursing in particular, has been challenging.

Here's Why You Should Retain Amedisys (AMED) Stock for Now

Amedisys's (AMED) share price is likely to grow following an impressive fourth-quarter 2022 performance and new partnerships.

Amedisys (AMED) Q4 Earnings Beat, Operating Margin Dips

Amedisys (AMED) delivers strong Home Health performance in the fourth quarter amid cost pressure.